436 related articles for article (PubMed ID: 32738955)
1. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.
Fitzgerald RC; di Pietro M; O'Donovan M; Maroni R; Muldrew B; Debiram-Beecham I; Gehrung M; Offman J; Tripathi M; Smith SG; Aigret B; Walter FM; Rubin G; ; Sasieni P
Lancet; 2020 Aug; 396(10247):333-344. PubMed ID: 32738955
[TBL] [Abstract][Full Text] [Related]
2. Barrett's oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux.
Offman J; Muldrew B; O'Donovan M; Debiram-Beecham I; Pesola F; Kaimi I; Smith SG; Wilson A; Khan Z; Lao-Sirieix P; Aigret B; Walter FM; Rubin G; Morris S; Jackson C; Sasieni P; Fitzgerald RC;
BMC Cancer; 2018 Aug; 18(1):784. PubMed ID: 30075763
[TBL] [Abstract][Full Text] [Related]
3. Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot.
Pilonis ND; Killcoyne S; Tan WK; O'Donovan M; Malhotra S; Tripathi M; Miremadi A; Debiram-Beecham I; Evans T; Phillips R; Morris DL; Vickery C; Harrison J; di Pietro M; Ortiz-Fernandez-Sordo J; Haidry R; Kerridge A; Sasieni PD; Fitzgerald RC
Lancet Oncol; 2022 Feb; 23(2):270-278. PubMed ID: 35030332
[TBL] [Abstract][Full Text] [Related]
4. Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study.
Ross-Innes CS; Chettouh H; Achilleos A; Galeano-Dalmau N; Debiram-Beecham I; MacRae S; Fessas P; Walker E; Varghese S; Evan T; Lao-Sirieix PS; O'Donovan M; Malhotra S; Novelli M; Disep B; Kaye PV; Lovat LB; Haidry R; Griffin M; Ragunath K; Bhandari P; Haycock A; Morris D; Attwood S; Dhar A; Rees C; Rutter MD; Ostler R; Aigret B; Sasieni PD; Fitzgerald RC;
Lancet Gastroenterol Hepatol; 2017 Jan; 2(1):23-31. PubMed ID: 28404010
[TBL] [Abstract][Full Text] [Related]
5. Real-world implementation of non-endoscopic triage testing for Barrett's oesophagus during COVID-19.
Landy R; Killcoyne S; Tang C; Juniat S; O'Donovan M; Goel N; Gehrung M; Fitzgerald RC
QJM; 2023 Sep; 116(8):659-666. PubMed ID: 37220898
[TBL] [Abstract][Full Text] [Related]
6. The Munich Barrett follow up study: suspicion of Barrett's oesophagus based on either endoscopy or histology only--what is the clinical significance?
Meining A; Ott R; Becker I; Hahn S; Mühlen J; Werner M; Höfler H; Classen M; Heldwein W; Rösch T
Gut; 2004 Oct; 53(10):1402-7. PubMed ID: 15361485
[TBL] [Abstract][Full Text] [Related]
7. Methylation panel is a diagnostic biomarker for Barrett's oesophagus in endoscopic biopsies and non-endoscopic cytology specimens.
Chettouh H; Mowforth O; Galeano-Dalmau N; Bezawada N; Ross-Innes C; MacRae S; Debiram-Beecham I; O'Donovan M; Fitzgerald RC
Gut; 2018 Nov; 67(11):1942-1949. PubMed ID: 29084829
[TBL] [Abstract][Full Text] [Related]
8. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study.
Ross-Innes CS; Debiram-Beecham I; O'Donovan M; Walker E; Varghese S; Lao-Sirieix P; Lovat L; Griffin M; Ragunath K; Haidry R; Sami SS; Kaye P; Novelli M; Disep B; Ostler R; Aigret B; North BV; Bhandari P; Haycock A; Morris D; Attwood S; Dhar A; Rees C; Rutter MD; Sasieni PD; Fitzgerald RC;
PLoS Med; 2015 Jan; 12(1):e1001780. PubMed ID: 25634542
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported experiences and views on the Cytosponge test: a mixed-methods analysis from the BEST3 trial.
Maroni R; Barnes J; Offman J; Scheibl F; Smith SG; Debiram-Beecham I; Waller J; Sasieni P; Fitzgerald RC; Rubin G; ; Walter FM
BMJ Open; 2022 Apr; 12(4):e054258. PubMed ID: 35393308
[TBL] [Abstract][Full Text] [Related]
11. Acceptability of the Cytosponge procedure for detecting Barrett's oesophagus: a qualitative study.
Freeman M; Offman J; Walter FM; Sasieni P; Smith SG
BMJ Open; 2017 Mar; 7(3):e013901. PubMed ID: 28255095
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data.
Swart N; Maroni R; Muldrew B; Sasieni P; Fitzgerald RC; Morris S;
EClinicalMedicine; 2021 Jul; 37():100969. PubMed ID: 34195582
[TBL] [Abstract][Full Text] [Related]
13. Quantification of TFF3 expression from a non-endoscopic device predicts clinically relevant Barrett's oesophagus by machine learning.
Berman AG; Tan WK; O'Donovan M; Markowetz F; Fitzgerald RC
EBioMedicine; 2022 Aug; 82():104160. PubMed ID: 35843173
[TBL] [Abstract][Full Text] [Related]
14. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study.
Kadri SR; Lao-Sirieix P; O'Donovan M; Debiram I; Das M; Blazeby JM; Emery J; Boussioutas A; Morris H; Walter FM; Pharoah P; Hardwick RH; Fitzgerald RC
BMJ; 2010 Sep; 341():c4372. PubMed ID: 20833740
[TBL] [Abstract][Full Text] [Related]
15. A non-endoscopic device to sample the oesophageal microbiota: a case-control study.
Elliott DRF; Walker AW; O'Donovan M; Parkhill J; Fitzgerald RC
Lancet Gastroenterol Hepatol; 2017 Jan; 2(1):32-42. PubMed ID: 28404012
[TBL] [Abstract][Full Text] [Related]
16. Simplified versus standard regimen for focal radiofrequency ablation of dysplastic Barrett's oesophagus: a multicentre randomised controlled trial.
Pouw RE; Künzli HT; Bisschops R; Sondermeijer CM; Koch AD; Didden P; Gotink AW; Schoon EJ; Curvers WL; Bergman JJGHM; Weusten BLAM
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):566-574. PubMed ID: 29934224
[TBL] [Abstract][Full Text] [Related]
17. Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device.
Heberle CR; Omidvari AH; Ali A; Kroep S; Kong CY; Inadomi JM; Rubenstein JH; Tramontano AC; Dowling EC; Hazelton WD; Luebeck EG; Lansdorp-Vogelaar I; Hur C
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1397-1404.e7. PubMed ID: 28238953
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of combined screening for upper gastrointestinal adenocarcinoma risk by serology and Cytosponge testing: the SUGAR study.
Xu Y; Miremadi A; Link A; Malfertheiner P; Fitzgerald RC; Bornschein J
J Clin Pathol; 2019 Dec; 72(12):825-829. PubMed ID: 31235543
[TBL] [Abstract][Full Text] [Related]
19. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study.
Peters FT; Ganesh S; Kuipers EJ; Sluiter WJ; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
Gut; 1999 Oct; 45(4):489-94. PubMed ID: 10486353
[TBL] [Abstract][Full Text] [Related]
20. Predictors of the experience of a Cytosponge test: analysis of patient survey data from the BEST3 trial.
Ghimire B; Landy R; Maroni R; Smith SG; Debiram-Beecham I; Sasieni PD; Fitzgerald RC; Rubin G; Walter FM; Waller J; ; Offman J
BMC Gastroenterol; 2023 Jan; 23(1):7. PubMed ID: 36627580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
